HomeAI · summaries
Storia in 2 fonti
Evommune's Skin Disorder Study Falls Short - Evommune (NYSE:EVMN)
Evommune said EVO756 failed to meet the primary endpoint in a Phase 2b CSU trial, ending development in the indication.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Evommune's lead drug fails in chronic hives, stock sinks
Evommune shares fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year.
- ·
benzinga.com
Evommune's Skin Disorder Study Falls Short - Evommune (NYSE:EVMN)
Evommune said EVO756 failed to meet the primary endpoint in a Phase 2b CSU trial, ending development in the indication.